Gelteq Limited income statement GELS

Annual Quarterly

Diluted earnings per share were -$0.72.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line
FY 2025
Jun 30, 2025
Basic EPS
-0.72
Diluted EPS
-0.72
Weighted average shares, basic
9
+14.2%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
GELS (Nasdaq)
Fiscal year ends
June 30
Incorporated in
Australia
Headquarters
South Melbourne Vic
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
1920092
Former names
Gelteq Pty Ltd. (until Mar 31, 2022)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.